Agentix Corp.

AGTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2023 FY2022 FY2021 FY2017 FY2016 FY2015
Revenue $0 $1.2K $1.2K $2.3K $43.1K $28.4K
Cost of Revenue $0 $561 $561 $1.4K $1.4K $2.0K
Gross Profit $0 $679 $679 $893 $41.8K $26.3K
Gross Margin — 54.8% 54.8% 39.7% 96.9% 92.8%
Operating Expenses
Research & Development $711.5K $279.9K $365.1K — $3.7K $28.3K
SG&A Expense $140.0K $165.4K $66.4K $23.7K $23.0K $36.3K
Operating Income $-1.4M $-2.6M $-1.3M $-334.0K $-292.4K $-175.1K
Operating Margin — -211,825.1% -108,092.9% -14,844.0% -677.8% -617.2%
Interest Expense $1.6K — — $13.3K — —
Pretax Income $-1.4M — $-1.3M $-381.1K $-295.6K —
Income Tax Expense $0 $0 $0 — — —
Net Income $-1.4M $-2.6M $-1.3M $-381.1K $-295.6K $-175.1K
Net Margin — -211,825.1% -108,092.5% -16,937.8% -685.2% -617.2%
EPS (Basic) — — $-0.04 $-0.06 $-0.05 $-0.03
EPS (Diluted) — — $-0.04 $-0.06 $-0.05 $-0.03
Shares Outstanding (Basic) 40.1M 38.9M 34.9M 6.0M 6.0M 6.0M
Shares Outstanding (Diluted) 40.1M 38.9M 34.9M 6.0M 6.0M 6.0M
Dividends Per Share — — — — — —